Pfizer's Ibrance conquers new breast cancer territory
This article was originally published in Scrip
Pfizer's new CDK4 and 6 inhibitor Ibrance (palbociclib) has hit its progression-free survival primary endpoint in the Phase III PALOMA-3 study in a new breast cancer population, stopping the trial early.
You may also be interested in...
Lilly highlighted five prognostic factors at SABCS that may be linked to high Verzenio response. As the third CDK4/6 inhibitor on the US market, the company needs to differentiate its breast cancer drug from Pfizer's Ibrance and Novartis's Kisqali.
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.